check_circleStudy Completed
HIV infections
Bayer Identifier:
10630
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Safety and Efficacy of BAY 50-4798 in Patients with HIV Infection
Trial purpose
The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.
Key Participants Requirements
Sex
BothAge
18 YearsTrial summary
Enrollment Goal
56Trial Dates
December 2002 - March 2005Phase
Phase 1/Phase 2Could I Receive a placebo
NoProducts
Interleukin-2 SA (BAY50-4798)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | London, SW10 9NH, United Kingdom | |
Completed | Birmingham, 35294-2050, United States | |
Completed | Sacramento, 95814, United States | |
Completed | Los Angeles, 90095-7156, United States | |
Completed | Chicago, 60612-3820, United States | |
Completed | San Francisco, 94115, United States | |
Completed | Bethesda, 20892, United States | |
Completed | CRETEIL, 94000, France | |
Completed | Chicago, 60611-2908, United States | |
Completed | Cleveland, 44106-3808, United States | |
Completed | Palo Alto, 94304-1207, United States | |
Withdrawn | PARIS, 75634, France | |
Withdrawn | Tulsa, 74127, United States | |
Withdrawn | Dallas, 75216-7167, United States |
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
RandomizedBlinding
Double BlindAssignment
Parallel AssignmentTrial Arms
2